Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

J Natl Cancer Inst 2019 Apr;111(4):380-387

Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.

Background: The prognostic relevance of circulating tumor cells (CTCs) at the time of primary diagnosis has been well established. However, little information is available regarding their prognostic relevance to follow-up care.

Methods: The multicenter, open-label, phase III SUCCESS A trial compared two adjuvant chemotherapy regimens followed by 2 vs 5 years of zoledronate for early-stage, high-risk breast cancer patients. The presence of CTCs was assessed before and 2 years after chemotherapy using the FDA-approved CellSearch System. Overall survival (OS) and disease-free survival (DFS) were analyzed using univariate log-rank tests and multivariable Cox regressions. OS and DFS were measured starting from an assessment of CTCs 2 years after the completion of chemotherapy. All statistical tests were two-sided.

Results: The sample included 1087 patients who participated in the translational research program of the SUCCESS A trial and for whom sufficient translational data were available regarding CTC status at baseline and at the 2-year follow-up visit. Two years after chemotherapy, 198 (18.2%) patients were CTC-positive. The median follow-up after this timepoint was 37 months. Cox regressions that included CTC status at baseline revealed that CTC status 2 years after chemotherapy had statistically significant and independent prognostic relevance for OS (hazard ratio [HR] = 3.91, 95% confidence interval [CI] = 2.04 to 7.52, P < .001) and DFS (HR = 2.31, 95% CI = 1.50 to 3.55, P < .001).

Conclusion: The presence of CTCs 2 years after chemotherapy was associated with decreased OS and DFS. Based on these results, active individualized surveillance strategies for breast cancer survivors based on biomarkers should be reconsidered.

Download full-text PDF

Source
https://academic.oup.com/jnci/advance-article/doi/10.1093/jn
Publisher Site
http://dx.doi.org/10.1093/jnci/djy152DOI Listing
April 2019
13 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 23, 2019, 2:28 am EST
twitter
Twitter:
April 9, 2019, 12:54 pm EST
twitter
Twitter: Aallan74
November 22, 2018, 10:10 pm EST
twitter
Twitter: JackRaph
November 22, 2018, 9:48 pm EST
twitter
Twitter: CeprecOaxaca
November 15, 2018, 8:22 am EST
twitter
Twitter: FlatinCanada
November 1, 2018, 12:56 pm EST
twitter
Twitter: DiepFlapBreast
November 1, 2018, 12:48 pm EST
twitter
Twitter: LguzzardiM
November 1, 2018, 12:47 pm EST
twitter
Twitter: JNCI_Now
October 24, 2018, 2:05 pm EST

Publication Analysis

Top Keywords

years chemotherapy
16
prognostic relevance
12
breast cancer
12
ctc status
12
cox regressions
8
success trial
8
status baseline
8
ctcs years
8
circulating tumor
8
tumor cells
8
presence ctcs
8
chemotherapy
6
years
6
years completion
4
dfs 231
4
starting assessment
4
assessment ctcs
4
chemotherapy statistical
4
sample included
4
752 001
4

References

(Supplied by CrossRef)
Cancer treatment and survivorship statistics
Siegel et al.
CA Cancer J Clin 2012
Cancer treatment and survivorship statistics
DeSantis et al.
CA Cancer J Clin 2014
Follow-up strategies for women treated for early breast cancer
Rojas et al.
Cochrane Database Syst Rev 2005
Follow-up strategies for women treated for early breast cancer
Moschetti et al.
Cochrane Database Syst Rev 2016
Follow-up strategies for women treated for early breast cancer
Rojas et al.
Cochrane Database Syst Rev 2000
Metastatic behavior of breast cancer subtypes
Kennecke et al.
J Clin Oncol 2010

Similar Publications